Trial Suggests Israeli Cannabis Jab Is Safe For Long-Term Therapy

An Israeli company that develops cannabis-based therapeutics has published successful results of a trial suggesting that its injectable treatment can be used safely in the long term.

Innocan Pharma is developing a jab that uses liposomes (small lipid-based spheres) to encapsulate cannabidiol (CBD) and release it at a controlled rate so as to maintain its concentration in the body at an effective level over a sustained period of time.

The injection was specifically designed to provide a longer exposure to CBD as compared to conventional oral treatments. 

The LPT-CBD treatment was administered to animals every few weeks for a period of over six months. The results consistently showed noticeable pain relief and increased mobility.

There were also no observable adverse effects, including changes to vital signs or blood count, which were checked several times after every injection.

Based on these findings, the company believes that the injection can be safely used for long-term and continuous treatment of chronic diseases in humans.

“Every successful treatment is a monumental step forward in our journey to revolutionize therapeutic care,” said Innocan Pharma CEO Iris Bincovich.

“The safety profile exhibited by LPT-CBD in this long-term treatment not only underscores our commitment to innovation, but also propels us closer to our goal of transforming patient care through sustained-release therapies,” she said.